Notocotylus loeiensis n. sp. (Trematoda: Notocotylidae) from Rattus losea (Rodentia: Muridae) in Thailand

por Chaisiri, K., Morand, S., Ribas, A.
Publicado 2011

Anti-programmed cell death protein-1/ligand-1 therapy in different cancers

por Homet Moreno, B, Ribas, A
Publicado 2015

Parasitic infections in relation to practices and knowledge in a rural village in Northern Thailand with emphasis on fish-borne trematode infection

por Chaisiri, K., Jollivet, C., Della Rossa, P., Sanguankiat, S., Wattanakulpanich, D., Lajaunie, C., Binot, A., Tanita, M., Rattanapikul, S., Sutdan, D., Morand, S., Ribas, A.
Publicado 2018

Chemical dissection of the cell cycle: probes for cell biology and anti-cancer drug development

por Senese, S, Lo, Y C, Huang, D, Zangle, T A, Gholkar, A A, Robert, L, Homet, B, Ribas, A, Summers, M K, Teitell, M A, Damoiseaux, R, Torres, J Z
Publicado 2014

Vemurafenib in patients with BRAF(V600) mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study

por Chapman, P B, Robert, C, Larkin, J, Haanen, J B, Ribas, A, Hogg, D, Hamid, O, Ascierto, P A, Testori, A, Lorigan, P C, Dummer, R, Sosman, J A, Flaherty, K T, Chang, I, Coleman, S, Caro, I, Hauschild, A, McArthur, G A
Publicado 2017

Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001

por Hamid, O, Robert, C, Daud, A, Hodi, F S, Hwu, W J, Kefford, R, Wolchok, J D, Hersey, P, Joseph, R, Weber, J S, Dronca, R, Mitchell, T C, Patnaik, A, Zarour, H M, Joshua, A M, Zhao, Q, Jensen, E, Ahsan, S, Ibrahim, N, Ribas, A
Publicado 2019

A phase Ib/II dose expansion study of subcutaneous sasanlimab in patients with locally advanced or metastatic non-small-cell lung cancer and urothelial carcinoma

por Cho, B.C., Penkov, K., Bondarenko, I., Kurochkin, A., Pikiel, J., Ahn, H.K., Korożan, M.E., Osipov, M., Odintsova, S., Braiteh, F., Ribas, A., Grilley-Olson, J.E., Lugowska, I., Bonato, V., Damore, M.A., Yang, W., Jacobs, I.A., Bowers, M., Li, M., Johnson, M.L.
Publicado 2023

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study

por Long, G. V., Flaherty, K. T., Stroyakovskiy, D., Gogas, H., Levchenko, E., de Braud, F., Larkin, J., Garbe, C., Jouary, T., Hauschild, A., Chiarion-Sileni, V., Lebbe, C., Mandalà, M., Millward, M., Arance, A., Bondarenko, I., Haanen, J. B. A. G., Hansson, J., Utikal, J., Ferraresi, V., Mohr, P., Probachai, V., Schadendorf, D., Nathan, P., Robert, C., Ribas, A., Davies, M. A., Lane, S. R., Legos, J. J., Mookerjee, B., Grob, J.-J.
Publicado 2017

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study

por Long, G V, Flaherty, K T, Stroyakovskiy, D, Gogas, H, Levchenko, E, de Braud, F, Larkin, J, Garbe, C, Jouary, T, Hauschild, A, Chiarion-Sileni, V, Lebbe, C, Mandalá, M, Millward, M, Arance, A, Bondarenko, I, Haanen, J B A G, Hansson, J, Utikal, J, Ferraresi, V, Mohr, P, Probachai, V, Schadendorf, D, Nathan, P, Robert, C, Ribas, A, Davies, M A, Lane, S R, Legos, J J, Mookerjee, B, Grob, J -J
Publicado 2019